Tietgen K, Schulz E, Boness J, Marre R
Immun Infekt. 1986 Jul;14(4):152-5.
Ciprofloxacin was tested in the acute and chronic experimental E.coli pyelonephritis in rats. Its therapeutic efficacy was compared with that of cefotaxime. In the acute pyelonephritis increasing doses resulted in increasing elimination of bacteria from the kidneys. Ciprofloxacin and cefotaxime showed no difference in the efficiency in therapy of the acute pyelonephritis. In chronic pyelonephritis ciprofloxacin proved to be more effective than cefotaxime in spite of identical in vitro activity. Pharmacokinetic data showed that ciprofloxacin was eliminated more slowly than cefotaxime. The long serum half-life and the high volume of distribution could be responsible for the high therapeutic efficacy and could outweigh the disadvantage of metabolic instability.
在大鼠急性和慢性实验性大肠杆菌肾盂肾炎模型中对环丙沙星进行了测试。将其治疗效果与头孢噻肟进行了比较。在急性肾盂肾炎中,剂量增加导致肾脏中细菌清除增加。环丙沙星和头孢噻肟在急性肾盂肾炎治疗效果上无差异。在慢性肾盂肾炎中,尽管环丙沙星和头孢噻肟体外活性相同,但环丙沙星被证明比头孢噻肟更有效。药代动力学数据表明,环丙沙星比头孢噻肟消除更慢。血清半衰期长和分布容积高可能是其高治疗效果的原因,且可能超过代谢不稳定的缺点。